• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PathAI Unveils New AI-Powered Pathology Tools for Cancer Research

by Syed Hamza Sohail 05/30/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–              PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights.

–              The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics.

 Enhancing Tumor Characterization and Biomarker Identification with AI-Driven Pathology Tools

The expansion of the Explore™ portfolio coincides with the rapid large-scale adoption of AI-pathology in the diagnostic and biopharma industries. This growth highlights the increasing importance of advanced diagnostic tools in improving patient outcomes.

A crucial element in determining which tumors are likely to respond to immunotherapy is the composition of the tumor immune microenvironment. PathExplore IOP accelerates the characterization of immune phenotypes by quantifying tumor-infiltrating lymphocytes (TILs) and their spatial distribution using routine hematoxylin and eosin (H&E) samples. This innovative product allows researchers to assess TIL spatial arrangements within the tumor core and periphery, providing insights into the sample’s immune-inflamed, desert, or excluded characteristics.

PathExplore IOP is specifically designed to quantify patterns of immune infiltration that indicate a strong immune response, ultimately leading to improved patient survival. Although immune infiltration has been shown to be prognostic of positive outcomes, standardized and scalable methods for investigating these phenotypes have been elusive until now.

In addition to PathExplore IOP, Immunohistochemistry (IHC) remains a widely utilized method for identifying cancer-specific biomarkers, informing treatment strategies, measuring prognosis, and classifying patients for clinical trials. However, IHC scoring in early clinical settings can be time-consuming, subjective, and low-resolution. Defining an optimal scoring system for a novel IHC assay, especially in early-stage biomarker development, presents a significant challenge.

IHC Explore™ addresses this need by providing spatial quantification of IHC biomarkers at single-cell resolution with broad target compatibility. It offers a panel of standardized and structured features to quantify IHC stain abundance within and around cells in the tumor microenvironment. This enables drug developers to build biomarker scoring strategies from scratch for most IHC stains, allowing for precise identification of patients most responsive to treatment.

PathAI’s partnership with Roche enhances the translation of these AI insights and scoring strategies into companion diagnostic development, streamlining the process and making it more efficient. Together, these advancements in AI-driven pathology tools are poised to significantly impact cancer diagnosis and treatment, offering new hope for improved patient outcomes.

“As cancer rates continue to rise, the demand for advanced precision medicine tools that provide accurate biological insights has never been greater. Our mission to make a difference in patient lives is unwavering, and these new products showcase our commitment to providing researchers with the tools they need to make meaningful advancements in cancer research, treatment and care,” said Andy Beck, PathAI CEO. “We’re thrilled to introduce these two groundbreaking products ahead of the American Society of Clinical Oncology annual meeting.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cancer Detection, Cancer Diagnostics, Digital Pathology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |